Recommended Dose of MMF for Lupus Nephritis
For adults with lupus nephritis, mycophenolate mofetil (MMF) should be dosed at 2-3 grams per day (1-1.5 grams twice daily), which translates to approximately 30-40 mg/kg/day for most patients, though weight-based dosing is not the standard approach in adults.
Adult Dosing
The most recent KDIGO 2024 and EULAR 2025 guidelines recommend mycophenolic acid analogs (MPAA, which includes MMF) as first-line therapy for active Class III/IV lupus nephritis 1, 2. However, neither guideline specifies mg/kg dosing for adults—they recommend fixed dosing instead.
- Standard adult dose: 1 gram twice daily (2 grams/day total) 1
- Higher dose option: 1.5 grams twice daily (3 grams/day total) was used in clinical trials, though no efficacy advantage was established over 2 grams/day, and the 2 gram dose showed a better safety profile 3
The FDA label for transplant patients (which provides the only official weight-independent dosing) recommends 1 gram twice daily for renal transplant, noting that 3 grams/day showed no additional efficacy benefit 3. Real-world data from Japan showed average doses <1.5 grams/day were commonly used 4, while a pharmacokinetic study found median doses of 1.5-2 grams/day during induction 5.
Pediatric Dosing (3 months to 18 years)
For children, MMF should be dosed at 600 mg/m² twice daily (up to maximum 2 grams/day), which typically translates to approximately 20-30 mg/kg/day 3, 6.
Specific pediatric recommendations:
- Body surface area 1.25-1.5 m²: 750 mg twice daily
- Body surface area >1.5 m²: 1 gram twice daily (same as adults)
- EULAR 2025 pediatric guidance: Starting dose of 0.6-1.0 mg/kg/day for glucocorticoids (not MMF), but acknowledges weight-based dosing remains the norm in pediatric practice 2
A pediatric study reported using MMF at a mean dose of 22 mg/kg/day (range 17-42 mg/kg/day) for lupus nephritis, though this was in treatment-refractory cases 6.
Important Clinical Considerations
Therapeutic drug monitoring may be superior to weight-based dosing: A 2014 pharmacokinetic study found that 61.8% of patients had subtherapeutic MPA exposure with empiric 30 mg/kg dosing, and that dose per body weight had only weak correlation with drug exposure 5. The study achieved 79.4% renal response using concentration-controlled dosing targeting AUC 30-60 mg·h/L, with median doses of 1.5-2 grams/day.
Key dosing pitfalls to avoid:
- Don't assume higher doses are better—3 grams/day showed worse safety without improved efficacy in transplant studies 3
- Patients with serum albumin <35 g/L may have lower drug exposure and require higher doses 5
- Severe renal impairment (GFR <25 mL/min/1.73 m²) requires dose reduction to avoid toxicity 3
- Concomitant antibiotics (ciprofloxacin, norfloxacin/metronidazole) can reduce MPA exposure by 30-50% 3
Combination therapy is now preferred over MMF monotherapy: The EULAR 2025 update strongly recommends combining MMF with belimumab, voclosporin, or obinutuzumab for patients with poor prognostic factors 2. The KDIGO 2024 guideline similarly endorses these combinations 1. While one case report described successful MMF monotherapy 7, this should be reserved only for patients who absolutely cannot tolerate glucocorticoids.
Bottom Line Algorithm
- Adults: Start 1 gram twice daily (2 grams/day total)
- Children: Start 600 mg/m² twice daily (max 2 grams/day)
- Consider therapeutic drug monitoring if available, targeting MPA AUC 30-60 mg·h/L
- Always combine with glucocorticoids (unless contraindicated) and strongly consider adding belimumab, voclosporin, or obinutuzumab for Class III/IV disease
- Reduce dose if GFR <25 mL/min/1.73 m² or if neutropenia develops (ANC <1.3 × 10³/µL)